Could Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) Skyrocket? The Stock Had Too Little Sellers

May 26, 2018 - By Ellis Scott

The stock of Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) registered a decrease of 40.46% in short interest. EYEG’s total short interest was 980,900 shares in May as published by FINRA. Its down 40.46% from 1.65M shares, reported previously. With 2.79M shares average volume, it will take short sellers 0 days to cover their EYEG’s short positions. The short interest to Eyegate Pharmaceuticals Inc’s float is 8.09%.

The stock decreased 4.19% or $0.03 during the last trading session, reaching $0.59. About 684,725 shares traded. EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) has declined 82.90% since May 26, 2017 and is downtrending. It has underperformed by 94.45% the S&P500.

EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing drug compositions and drug delivery systems for treating diseases and disorders of the eye. The company has market cap of $24.71 million. The firm is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients; and uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea. It currently has negative earnings. It is also developing the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial defects, as well as to accelerate re-epithelization of the ocular surface following surgery, injection, and other traumatic and non-traumatic conditions.

More important recent EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) news were published by: Globenewswire.com which released: “EyeGate Pharmaceuticals Announces New Board Member, Steven Boyd” on May 16, 2018, also Seekingalpha.com published article titled: “EyeGate advancing toward OBG IND”, Nasdaq.com published: “EyeGate Addresses Majority of FDA’s Action Items with Submission of Investigational Device Exemption Amendment …” on May 22, 2018. More interesting news about EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) was released by: Seekingalpha.com and their article: “Reader Inquiry: Time To Buy EyeGate Pharmaceuticals?” with publication date: May 18, 2018.

EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: